Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

NCT01382706 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Trial not progressing toward scientific goals

Conditions

Recurrent Bladder Cancer
Stage III Bladder Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions

DRUG: docetaxel
DRUG: lapatinib ditosylate
OTHER: immunohistochemistry staining method
GENETIC: fluorescence in situ hybridization
OTHER: laboratory biomarker analysis

Sponsor

University of Southern California

Collaborators

[object Object]
[object Object]